Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib and MMF Interaction Study in Healthy Males
NCT03660436Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deucravacitinib in plaque psoriasis and systemic lupus erythematosus (SLE), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum plasma concentration of mycophenolic acid (MPA) at 18 days, Area under the concentration vs time curve from time zero to the last quantifiable plasma concentration of MPA at 18 days and 1 more. Started Aug 2018; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasissystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03660436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03660436.